

Appl. No. 10/027,269

Amendment dated May 22, 2003

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): An absorbent device adapted to deliver a therapeutic agent to a user, the device comprising:

a body having a proximal end and a distal end and adapted to be positioned entirely within the user, the body including

an absorbency zone adjacent the distal end, wherein the absorbency zone includes absorbent material;

an application zone adjacent the proximal end and spaced apart from the distal end, wherein the application zone has a surface; and

AZ a formulation including a therapeutic agent positioned substantially adjacent the surface within the application zone.

Claim 2 (original): The device of claim 1, wherein the device is a catamenial device.

Claim 3 (original): The device of claim 1, wherein the device is an incontinence device.

Claim 4 (original): The device of claim 1, wherein the device is a tampon.

Claim 5 (original): The device of claim 1, wherein the application zone includes absorbent material.

Claim 6 (original): The device of claim 1, wherein the application zone includes non-absorbent material.

Claim 7 (original): The device of claim 1, wherein the application zone consists essentially of non-absorbent material.

Appl. No. 10/027,269

Amendment dated May 22, 2003

Claim 8 (original): The device of claim 1, further comprising a reservoir within the application zone, wherein the formulation including the therapeutic agent is located substantially within the reservoir.

Claim 9 (original): The device of claim 8, wherein the reservoir is in communication with the surface.

Claim 10 (original): The device of claim 8, wherein the reservoir is located under the surface.

AZ
Claim 11 (original): The device of claim 1, wherein the formulation including a therapeutic agent is substantially a liquid.

Claim 12 (original): The device of claim 1, wherein the formulation including a therapeutic agent is substantially a solid.

Claim 13 (original): The device of claim 1, wherein the formulation including a therapeutic agent is substantially a semi-solid.

Claim 14 (original): The device of claim 1, wherein the formulation including a therapeutic agent is encapsulated.

Claim 15 (canceled)

Claim 16 (canceled)

Claim 17 (original): The device of claim 1, wherein the therapeutic agent is adapted to treat dysmenorrhea.

Appl. No. 10/027,289

Amendment dated May 22, 2003

Claim 18 (original): The device of claim 1, wherein the therapeutic agent is selected from the group consisting of: Celecoxib, Meloxicam, Rofecoxib, and Flosulide.

Claim 19 (original): The device of claim 1, wherein the therapeutic agent is selected from the group consisting of: Aspirin, Ibuprofen, Indomethacin, Phenylbutazone, Bromfenac, Sulindac, Nabumetone, Ketorolac, Mefenamic Acid, and Naproxen.

Claim 20 (original): The device of claim 1, wherein the therapeutic agent is selected from the group consisting of: Lidocaine, Mepivacaine, Etidocaine, Bupivacaine, 2-Chloroprocaine hydrochloride, Procaine, and Tetracaine hydrochloride.

A 2
Claim 21(original): The device of claim 1, wherein the therapeutic agent is selected from the group consisting of: Diltiazem, Isradipine, Nimodipine, Felodipine, Verapamil, Nifedipine, Nicardipine, and Bepridil.

Claim 22 (original): The device of claim 1, wherein the therapeutic agent is selected from the group consisting of: Dofetilide, E-4031, Imokalan, Sematilide, Ambasilide, Azimilide, Ted isamil, RP58866, Sotalol, Piroxicam, and Ibutilide.

Claim 23 (original): The device of claim 1, wherein the therapeutic agent is selected from the group consisting of: Terbutaline, Salbutamol, Metaproterenol, and Ritodrine.

Claim 24 (original): The device of claim 1, wherein the therapeutic agent is selected from the group consisting of: nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate.

Claim 25 (original): The device of claim 1, wherein the therapeutic agent is selected from the group consisting of: Celecoxib, Meloxicam, Rofecoxib, and Flosulide.

Appl. No. 10/027,269

Amendment dated May 22, 2003

Claim 26 (original): The device of claim 1, wherein the therapeutic agent is selected from the group consisting of: *Agnus castus*, aloe vera, comfrey, calendula, dong quai, black cohosh, chamomile, evening primrose, *Hypericum perforatum*, licorice root, black currant seed oil, St. John's wort, tea extracts, lemon balm, capsicum, rosemary, *Areca catechu*, mung bean, borage seed oil, witch hazel, fenugreek, lavender, and soy.

Claim 27 (original): The device of claim 1, wherein the therapeutic agent is a *Vaccinium* extract derived from a plant selected from the group consisting of: heath, cranberries, blueberries, azaleas, red onion skin, short red bell peppers, long red bell peppers, beet root extract, and capsanthin.

A2 Claim 28 (original): The device of claim 1, wherein the therapeutic agent is selected from the group consisting of: whortleberry, lingonberry, chokeberry, sweet rowan, rowanberry, seabuckthrouberry, crowberry, strawberries, and gooseberries.

Claim 29 (original): The device of claim 1, wherein the therapeutic agent is a combination of a botanical and a beneficial agent selected from the group consisting of: vitamins, calcium, magnesium, hormones, analgesics, prostaglandin inhibitors, prostaglandin synthetase inhibitors, leukotriene receptor antagonists, essential fatty acids, sterols, anti-inflammatory agents, vasodilators, chemotherapeutic agents, and agents to treat infertility.

Claim 30 (original): The device of claim 1, further comprising a pledget, wherein the formulation including a therapeutic agent is applied to the pledget.

Claim 31 (original): The device of claim 1, wherein the formulation including a therapeutic agent is applied to the surface.

Claim 32 (original): The device of claim 1, wherein the formulation including a therapeutic agent is applied to degradable fibers.

Appl. No. 10/027,269

Amendment dated May 22, 2003

Claim 33 (original): The device of claim 1, wherein the body is compressed, and wherein the formulation including a therapeutic agent is applied to the body after the body is compressed.

Claim 34 (original): The device of claim 1, wherein the body is constructed from a material, and wherein the formulation including a therapeutic agent is applied to the material before the body is constructed.

Claim 35 (original): The device of claim 1, wherein the formulation including a therapeutic agent includes a hydrogel material.

A2
Claim 36 (original): The device of claim 1, wherein the body includes an apertured web, and wherein the formulation including a therapeutic agent is contained in the apertured web.

Claim 37 (original): The device of claim 1, wherein the formulation including a therapeutic agent includes a foam component.

Claim 38 (original): The device of claim 1, wherein the formulation including a therapeutic agent includes a polymeric material.

Claim 39 (currently amended): An absorbent device adapted to deliver a therapeutic agent to a user, the device comprising:

a body having a proximal end and a distal end and adapted to be positioned entirely within the user, the body including

an absorbency zone adjacent the distal end, wherein the absorbency zone includes absorbent material;

an application zone adjacent the proximal end and spaced apart from the distal end;

a reservoir within the application zone; and

a formulation including a therapeutic agent positioned substantially within the reservoir in the application zone.

Appl. No. 10/027,269

Amendment dated May 22, 2003

Claim 40 (original): The device of claim 39, wherein the application zone has a surface, and wherein the reservoir is in communication with the surface.

Claim 41 (original): The device of claim 39, wherein the application zone has a surface, and wherein the reservoir is located under the surface.

Claim 42 (original): The device of claim 39, further comprising an applicator, wherein pressure applied by the applicator to the body releases the therapeutic agent from the application zone.

Claim 43 (canceled)

A2
Claim 44 (currently amended): A method for producing a device for delivering a therapeutic agent to a user, the method comprising:

manufacturing a tampon having a body with a distal end, a proximal end, an absorbency zone adjacent the distal end, and an application zone adjacent the proximal end, wherein the body is adapted to be positioned entirely within the user, and wherein the application zone has a surface; and

locating a formulation including a therapeutic agent substantially adjacent the surface within the application zone.

Claim 45 (original): The method of claim 44, further comprising providing a tampon applicator such that pressure from the tampon applicator on the body releases the therapeutic agent from the application zone.

Claim 46 (original): The method of claim 44, wherein the manufacturing act includes manufacturing the body including a pledget, and wherein the locating act includes applying the formulation including a therapeutic agent to the pledget.

Appl. No. 10/027,269

Amendment dated May 22, 2003

Claim 47 (original): The method of claim 44, wherein the manufacturing act includes compressing the body, and wherein the locating act includes applying the formulation including a therapeutic agent to the body after the body is compressed.

Claim 48 (original): The method of claim 44, wherein the manufacturing act includes manufacturing the body from a material, and wherein the locating act includes applying the formulation including a therapeutic agent to the material before the body is manufactured.

Claim 49 (original): The method of claim 44, wherein the manufacturing act includes manufacturing the body to include an apertured web, and wherein the locating act includes containing the formulation including a therapeutic agent in the apertured web.

A2
Claim 50 (original): The method of claim 44, wherein the locating act includes producing the formulation including a therapeutic agent integrally with the device.

Claim 51 (currently amended): A tampon for delivering a therapeutic agent to a user, the tampon device comprising:

a body having a distal end, an absorbent portion adjacent the distal end, and an application zone spaced apart from the distal end, wherein the body is adapted to be positioned entirely within the user, and

a means for carrying a therapeutic agent within the application zone.

Claim 52 (original): The tampon of claim 51, wherein the application zone has a surface, and wherein the carrying means is substantially positioned adjacent the surface.

Claim 53 (original): The tampon of claim 51, wherein the application zone has a reservoir, and wherein the carrying means is substantially positioned within the reservoir.

Claim 54 (canceled)

Appl. No. 10/027,269

Amendment dated May 22, 2003

Claim 55 (new): An absorbent device adapted to deliver a therapeutic agent, the device comprising:
a body having a proximal end and a distal end, the body including

an absorbency zone adjacent the distal end, wherein the absorbency zone includes absorbent material;

an application zone adjacent the proximal end and spaced apart from the distal end, wherein the application zone has a surface, and wherein the application zone consists essentially of non-absorbent material; and

A3 a formulation including a therapeutic agent positioned substantially adjacent the surface within the application zone.

Claim 56. (new): A method for producing a device for delivering a therapeutic agent, the method comprising:

manufacturing a tampon having a body with a distal end, a proximal end, an absorbency zone adjacent the distal end, and an application zone adjacent the proximal end, wherein the application zone has a surface;

compressing the body; and

locating a formulation including a therapeutic agent substantially adjacent the surface within the application zone after the body is compressed.
